These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12437474)

  • 1. Pharmacogenomics of arylamine N-acetyltransferases--from drug metabolism to drug discovery.
    Sim E
    Pharmacogenomics; 2002 Nov; 3(6):729-31. PubMed ID: 12437474
    [No Abstract]   [Full Text] [Related]  

  • 2. Arylamine N-acetyltransferases and drug response.
    Meisel P
    Pharmacogenomics; 2002 May; 3(3):349-66. PubMed ID: 12052143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arylamine N-acetyltransferases--from drug metabolism and pharmacogenetics to identification of novel targets for pharmacological intervention.
    Sim E; Fakis G; Laurieri N; Boukouvala S
    Adv Pharmacol; 2012; 63():169-205. PubMed ID: 22776642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug acetylator phenotypes in newborn infants.
    Szórády I; Sánta A; Veress I
    Biol Res Pregnancy Perinatol; 1987; 8(1 1ST Half):23-5. PubMed ID: 3580445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N-acetyltransferases: lessons learned from eighty years of research.
    Agúndez JA
    Curr Drug Metab; 2008 Jul; 9(6):463-4. PubMed ID: 18680465
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic polymorphisms of drug metabolism.
    Meyer UA; Zanger UM; Skoda RC; Grant D; Blum M
    Prog Liver Dis; 1990; 9():307-23. PubMed ID: 2156298
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacogenetics of the arylamine N-acetyltransferases: a symposium in honor of Wendell W. Weber.
    Hein DW; McQueen CA; Grant DM; Goodfellow GH; Kadlubar FF; Weber WW
    Drug Metab Dispos; 2000 Dec; 28(12):1425-32. PubMed ID: 11095579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics: bench to bedside.
    Weinshilboum R; Wang L
    Nat Rev Drug Discov; 2004 Sep; 3(9):739-48. PubMed ID: 15340384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of the arylamine N-acetyltransferases.
    Butcher NJ; Boukouvala S; Sim E; Minchin RF
    Pharmacogenomics J; 2002; 2(1):30-42. PubMed ID: 11990379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arylamine N-acetyltransferases.
    Sim E; Westwood I; Fullam E
    Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):169-84. PubMed ID: 17428149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacogenetics of NAT: structural aspects.
    Pompeo F; Brooke E; Kawamura A; Mushtaq A; Sim E
    Pharmacogenomics; 2002 Jan; 3(1):19-30. PubMed ID: 11966400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic polymorphisms in drug metabolism--its relevance to Asian populations.
    Lee EJ
    Ann Acad Med Singap; 1991 Jan; 20(1):56-60. PubMed ID: 2029165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pivotal role of drug metabolism and pharmacokinetics in the discovery and development of new medicines.
    Alavijeh MS; Palmer AM
    IDrugs; 2004 Aug; 7(8):755-63. PubMed ID: 15334309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics in the practice of laboratory medicine.
    Linder MW; Valdes R
    Mol Diagn; 1999 Dec; 4(4):365-79. PubMed ID: 10671647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global patterns of genetic diversity and signals of natural selection for human ADME genes.
    Li J; Zhang L; Zhou H; Stoneking M; Tang K
    Hum Mol Genet; 2011 Feb; 20(3):528-40. PubMed ID: 21081654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of genetic polymorphisms in risk assessment of drugs.
    Poulsen HE; Loft S
    Arch Toxicol Suppl; 1994; 16():211-22. PubMed ID: 8192584
    [No Abstract]   [Full Text] [Related]  

  • 17. [Pharmacogenetics and pharmacogenomics. Searching for individual antihypertensive therapy concepts].
    Brand E
    MMW Fortschr Med; 2003 May; 145(19):43-4. PubMed ID: 12813978
    [No Abstract]   [Full Text] [Related]  

  • 18. Acetylator genotype-dependent expression of arylamine N-acetyltransferase and N-hydroxyarylamine O-acetyltransferase in Syrian inbred hamster intestine and colon. Identity with the hepatic acetylation polymorphism.
    Ogolla F; Ferguson RJ; Kirlin WG; Trinidad A; Andrews AF; Mpezo M; Hein DW
    Drug Metab Dispos; 1990; 18(5):680-5. PubMed ID: 1981720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylation pharmacogenetics. The slow acetylator phenotype is caused by decreased or absent arylamine N-acetyltransferase in human liver.
    Grant DM; Mörike K; Eichelbaum M; Meyer UA
    J Clin Invest; 1990 Mar; 85(3):968-72. PubMed ID: 2312737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular pharmacology of polymorphic arylamine N-acetyltransferase involved in the metabolism of arylamine drugs].
    Deguchi T
    Nihon Rinsho; 1992 Apr; 50(4):877-86. PubMed ID: 1619774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.